Simpara is announcing that four of their esteemed clients will be honored by Health Rosetta Institute for providing employees one of “America’s Top 50 Health Plans.”
Humira Biosimilar Boom
July is Humira Biosimilar Month
Gag Clause Prohibition: Plan Sponsors Are Entitled to their Full Data
Humira Competition Begins
Amjevita, the first biosimilar competitor to Humira hit the U.S. market at the end of January. Showcasing the dysfunction of our healthcare delivery system, the copycat drug came to market with two drastically different list prices. One, a mere 5% discount relative to Humira and another with a 55% discount. Why two prices and who would pay for the more expensive option?
DOL Christmas Gift - CAA Reporting
ACA "Family Glitch" Could Soon Be Resolved
This Little Device Will Save your Health Plan Big Bucks
The Blockbuster Drug of our Lifetime Loses its Monopoly Status on January 1, 2023
In 2003, a little drug named Humira hit the market under the name DE27. Analysts believed at the time that Humira, which was approved to treat Rheumatoid Arthritis, would eventually generate between $500M and $1B in sales annually. In 2021, Humira’s global sales totaled $20.7B. Lifetime earnings have eclipsed $200B.
Supreme Court Rules Against DaVita: What This Decision Means for Self-Insured Plans
Sunshine is the Best Disinfectant
Take a Peek Behind the Curtain at Healthcare Costs in the U.S.
Hidden no more. The Employers’ Forum of Indiana (EFI) is giving people a look behind the curtain at the reality of hospital costs in the United States.
What began as the first hospital price transparency study in the U.S., commissioned by EFI and conducted by RAND Corporation back in 2017, eventually became the foundation for the Employer Hospital Price Transparency Project.
